Canopy Growth

Global Cannabis Legalization Will Unlock Medical And Wellness Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

10 Aug 25

Updated

16 Aug 25

AnalystHighTarget's Fair Value

CA$8.00

76.3% undervalued

16 Aug

CA$1.90

-79.0%

-12.8%

Author's Valuation

CA$8.0

76.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CA$8.0

76.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

6.82%

Pharma revenue growth rate

0.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.97%

Calculation

CA$167.76m

Earnings '28

29.90x

PE Ratio '28

CA$5.02b

Market Cap '28

CA$5.02b

Market Cap '28

526.95m

No. shares '28

CA$9.52

Share Price '28

CA$9.52 Share Price '28

Discounted to 2025 @ 5.97% p.a.

CA$8.00

Fair Value '25